Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, April 10th.
According to Zacks, “Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. Among new products, the company redefined its strategy for Kanuma as the drug lagged expectations. Meanwhile, in order to focus better in core areas, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma. However, the company relies heavily on Soliris for growth and sales of the same will be impacted increased ALXN1210 trials. Pricing is also projected to hit revenues by 3% in 2018. Shares of the company have underperformed the industry over a year.”
A number of other equities research analysts have also recently commented on the stock. Deutsche Bank set a $161.00 target price on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, March 15th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $149.00 target price (up from $147.00) on shares of Alexion Pharmaceuticals in a report on Friday, March 16th. Robert W. Baird set a $160.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 15th. Nomura increased their price target on shares of Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a report on Thursday, March 15th. Finally, BidaskClub raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, March 17th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and twenty have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $155.95.
Shares of ALXN stock opened at $112.96 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. The firm has a market cap of $25,188.75, a P/E ratio of 21.89, a PEG ratio of 1.01 and a beta of 1.13. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The firm had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. During the same quarter in the previous year, the firm posted $1.26 earnings per share. The company’s revenue was up 9.5% compared to the same quarter last year. sell-side analysts anticipate that Alexion Pharmaceuticals will post 6.12 earnings per share for the current year.
In other news, SVP Heidi L. Wagner sold 655 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total value of $76,805.30. Following the transaction, the senior vice president now owns 32,635 shares of the company’s stock, valued at approximately $3,826,780.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Heidi L. Wagner sold 698 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $119.35, for a total transaction of $83,306.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,700 shares of company stock worth $3,345,708. 4.35% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the company. Delpha Capital Management LLC purchased a new position in shares of Alexion Pharmaceuticals in the 4th quarter valued at $102,000. Valeo Financial Advisors LLC purchased a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $147,000. CNB Bank purchased a new position in shares of Alexion Pharmaceuticals in the 4th quarter valued at $150,000. Beacon Investment Advisory Services Inc. purchased a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $201,000. Finally, Lourd Capital LLC purchased a new position in shares of Alexion Pharmaceuticals in the 4th quarter valued at $221,000. 95.09% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals (NASDAQ:ALXN) Upgraded at Zacks Investment Research” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/04/19/zacks-investment-research-upgrades-alexion-pharmaceuticals-alxn-to-hold.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.